Pitfalls in the radiological response assessment of immunotherapy
Author:
Funder
Oesterreichische Nationalbank
Theodor Koerner Fond
Krebsforschungsfond der Stadt Wien
Medical University of Vienna
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology
Link
http://link.springer.com/article/10.1007/s12254-018-0389-x/fulltext.html
Reference29 articles.
1. Kwak JJ, et al. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics. 2015;35(2):424–37.
2. Allen PB, Gordon LI. PD-1 blockade in Hodgkin’s lymphoma: learning new tricks from an old teacher. Expert Rev Hematol. 2016;9(10):939–49.
3. Sonpavde G. PD-1 and PD-L1 inhibitors as salvage therapy for urothelial carcinoma. N Engl J Med. 2017;376(11):1073. https://doi.org/10.1056/NEJMe1701182 .
4. Rizvi NA, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257–65.
5. Nishino M, et al. Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions. Clin Cancer Res. 2017;23(16):4671. https://doi.org/10.1158/1078-0432.CCR-17-0114 .
Cited by 65 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Delta Radiomics — Potential Role in Head Neck Cancer;2024-04-23
2. Delta Radiomics — Potential Role in Head Neck Cancer;2024-04-15
3. Metabolic tumor volume and sites of organ involvement predict outcome in NSCLC immune-checkpoint inhibitor therapy;European Journal of Radiology;2024-01
4. Delta-radiomics in cancer immunotherapy response prediction: A systematic review;European Journal of Radiology Open;2023-12
5. Plasma Immune Proteins and Circulating Tumor DNA Predict the Clinical Outcome for Non-Small-Cell Lung Cancer Treated with an Immune Checkpoint Inhibitor;Cancers;2023-11-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3